PMID- 33495829 OWN - NLM STAT- MEDLINE DCOM- 20210504 LR - 20210702 IS - 1791-3004 (Electronic) IS - 1791-2997 (Print) IS - 1791-2997 (Linking) VI - 23 IP - 3 DP - 2021 Mar TI - Bioinformatics analysis identifies biomarkers associated with poor prognosis in diffuse‑type gastric cancer. LID - 193 [pii] LID - 10.3892/mmr.2021.11832 [doi] AB - Gastric cancer (GC) is one of the most common malignancies of the digestive system. In diffuse‑type GC, differentiation is relatively poor, and the probability of distant metastasis and lymph node metastasis is high, resulting in poor clinical prognosis. The purpose of this study was to identify specific genes that can predict the prognosis of different types of GC. Differentially expressed genes (DEGs) were screened in the GSE62254 dataset obtained from the Gene Expression Omnibus using the 'limma' and 'survival' R packages. A total of 355 survival‑related DEGs were selected according to specific screening criteria, of which 293 were associated with diffuse‑type GC and 62 with intestinal‑type GC. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes were used for functional annotation and pathway enrichment analysis of DEGs. Using protein‑protein interaction networks and Cytoscape software, three hub genes were identified in diffuse‑type GC‑associated DEGs, including angiotensinogen (AGT), C‑X‑C motif chemokine ligand 12 (CXCL12) and adrenoceptor beta2 (ADRB2). Immunohistochemical staining and reverse transcription‑quantitative PCR revealed that the expression levels of the three genes in diffuse‑type GC samples were upregulated compared with in intestinal‑type GC samples. Kaplan Meier analysis indicated that a higher expression levels of these three hub genes were associated with a poorer prognosis of diffuse‑type GC. In summary, the present findings suggested that AGT, CXCL12 and ADRB2 might contribute to the progression of diffuse‑type GC, and could serve as potential biomarkers or therapeutic targets for this disease. FAU - Li, Sheng AU - Li S AD - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230061, P.R. China. FAU - Yu, Chao AU - Yu C AD - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230061, P.R. China. FAU - Cheng, Yuanguang AU - Cheng Y AD - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230061, P.R. China. FAU - Du, Fangchao AU - Du F AD - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230061, P.R. China. FAU - Wen, Gang AU - Wen G AD - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230061, P.R. China. LA - eng PT - Journal Article DEP - 20210126 PL - Greece TA - Mol Med Rep JT - Molecular medicine reports JID - 101475259 RN - 0 (Biomarkers, Tumor) RN - 0 (Neoplasm Proteins) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*biosynthesis/genetics MH - Computational Biology MH - Databases, Nucleic Acid MH - Female MH - Gene Expression Profiling MH - *Gene Expression Regulation, Neoplastic MH - *Gene Regulatory Networks MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Proteins/genetics/*metabolism MH - *Protein Interaction Maps MH - Stomach Neoplasms/genetics/*metabolism/pathology PMC - PMC7809905 OTO - NOTNLM OT - gastric cancer OT - diffuse‑type OT - bioinformatics OT - differentially expressed gene EDAT- 2021/01/27 06:00 MHDA- 2021/05/05 06:00 PMCR- 2021/01/07 CRDT- 2021/01/26 05:50 PHST- 2020/05/23 00:00 [received] PHST- 2020/10/15 00:00 [accepted] PHST- 2021/01/26 05:50 [entrez] PHST- 2021/01/27 06:00 [pubmed] PHST- 2021/05/05 06:00 [medline] PHST- 2021/01/07 00:00 [pmc-release] AID - 193 [pii] AID - MMR-0-0-11832 [pii] AID - 10.3892/mmr.2021.11832 [doi] PST - ppublish SO - Mol Med Rep. 2021 Mar;23(3):193. doi: 10.3892/mmr.2021.11832. Epub 2021 Jan 26.